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Abstract
Background: NK cells are key players in anti tumor immune response, which can be employed in cell-based therapeutic
modalities. One of the suggested ways to amplify their anti tumor effect, especially in the field of stem cell transplantation,
is by selecting donor/recipient mismatches in specific HLA, to reduce the inhibitory effect of killer Ig-like receptors (KIRs).
Here we suggest an alternative approach for augmentation of anti tumor effect of allogeneic NK cells, which is founded on
profile matching of donor NK lysis receptors (NKLR) phenotype with tumor lysis-ligands.
Methodology/Principal Findings: We show that an NKLR-mediated killing directly correlates with the NKLR expression
intensity on NK cells. Considerable donor variability in the expression of CD16, NKp46, NKG2D and NKp30 on circulating NK
cells, combined with the stability of phenotype in several independently performed tests over two months, indicates that
NKLR-guided selection of donors is feasible. As a proof of concept, we show that melanoma cells are dominantly recognized
by three NKLRs: NKG2D, NKp30 and NKp44. Notably, the expression of NKp30 on circulating NK cells among metastatic
melanoma patients was significantly decreased, which diminishes their ability to kill melanoma cells. Ex vivo expansion of NK
cells results not only in increased amount of cells but also in a consistently superior and predictable expression of NKG2D,
NKp30 and NKp44. Moreover, expanded NK cultures with high expression of NKG2D or NKp30 were mostly derived from the
corresponding NKG2D
high or NK30
high donors. These NK cultures subsequently displayed an improved cytotoxic activity
against melanoma in a HLA/KIR-ligand mismatched setup, which was NKLR-dependent, as demonstrated with blocking anti-
NKG2D antibodies.
Conclusions/Significance: NKLR/NKLR-ligand matching reproducibly elicits enhanced NK anti-tumor response. Common
NKLR recognition patterns of tumors, as demonstrated here in melanoma, would allow implementation of this approach in
solid malignancies and potentially in hematological malignancies, either independently or in adjunction to other modalities.
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Introduction
Natural Killer (NK) cells are lymphocytes that belong to the
innate immune branch, comprise 5–15% of the peripheral blood
lymphocytes and are able to eliminate without prior antigenic
stimulation virus-infected and malignantly transformed cells, but
to spare normal healthy cells [1–2]. NK cells eliminate tumor cells
through perforin/granzyme dependent mechanisms, apoptotic
mechanism and through secretion of various inflammatory and
Th1-promoting cytokines [reviewed in 3–4]. NK cells respond to a
variety of bioactive agents, including cytokines such as interleukin-
2 (IL-2), IL-12, or interferons, by up-regulation of cytolytic,
secretory, and/or proliferative functions [5].
Triggering of effector NK cell functions depends on a balance
between inhibitory and stimulating signals [reviewed in 1, 4]. Most
inhibitory signals are mediated through Killer Ig-like Receptors
(KIR) that recognize various alleles of major histocompatibility
complex (MHC) class I molecules [6], and it was postulated that all
NK cells express at least one receptor that recognizes a self MHC
allele, probably to avoid autoreactivity [7]. However, recent
evidence show that up to 20% of the peripheral blood NK cells
may be KIR-negative, yet self-tolerant, as these cells probably
reflect an immature stage [8–10]. In addition, MHC class I
independent NK inhibitory mechanisms have already been
reported [11–12]. NK Lysis Receptors (NKLR) are collectively
comprised from the family of natural cytotoxicity receptors (NCR)
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from other main killing receptors such as NKG2D [16] and CD16
[17]. Ligands for some NKLRs are found on abnormal cells, such
as virus-infected, transformed or stressed cells [4]. Ligands for
other NKLRs, such as NKG2D, are not restricted to abnormal
cells, but are usually overexpressed under various conditions [18].
Notably, while the cellular ligands for the NCRs are still
undefined, several ligands for NKG2D have been identified and
include MICA, MICB, ULBP1, ULBP2, ULBP3 and ULBP4
[18]. CD16 is the high affinity FccRIII receptor [19], but a
cellular ligand is yet to be described. So far, the tumor ligands for
the NKLRs are still elusive, as only two viral ligands were
identified: hemagglutinins of paramyxoviridae viruses are recog-
nized by NKp46 [20] and NKp44 [21], and the CMV tegument
protein pp65 that is recognized by NKp30 [22].
The suppression of NK cells by self MHC class I might be a
mechanism that enables malignantly transformed cells to evade
NK-mediated elimination. Since KIR-ligands on tumors always
match the self NK cell KIR repertoire, autolgous NK cells are
constantly susceptible to inhibition. This may at least partially
explain the past clinical failure of adoptively transferred autolo-
gous NK or lymphokine activated killer (LAK) cells to mediate
objective rejection of metastatic solid malignancies [23–24]. These
notions led to the development of the KIR/KIR-ligand mismatch
concept to augment anticancer NK-mediated activity [25–27].
This concept can be employed only in an allogeneic setting. The
use of allogeneic NK cells has shown substantial clinical benefit
against acute myeloid leukemia (AML) after haploidentical and
partially mismatched unrelated hematopoietic cell transplantation
when KIR/KIR-ligand incompatibility existed in the graft-versus-
host (GVH) direction [26]. Surprisingly, in contrast to allogeneic T
cells, NK cells seem to have an anti GVH effect [26]. A similar
approach based on KIR/KIR-ligand mismatching was pre-
clinically developed for allogeneic NK adoptive cell transfer
(ACT) in solid malignancies [28]. So far, there is still only limited
clinical experience with KIR/KIR-ligand mismatching NK ACT
in solid malignancies [29–30].
The prevalence of malignant melanoma (MM) is continuously
rising, effectively almost tripling over the last 30 years [31].
Usually, MM is diagnosed at an early-stage and is completely
amenable to primary surgical treatment. However, MM is
sometimes characterized by an aggressive course with widespread
metastasis and poor prognosis. Immunomodulating drugs, such as
IL-2 comprise the mainstay of systemic therapeutic modalities in
disseminated MM [32]. Overall, objective clinical benefits are
evident in approximately 20% of the patients treated with IL-2,
with some of the patients exhibiting complete response and
uncommonly even cure [32]. Recently, attention to cell-based
therapy in melanoma has been growing again, especially with
tumor infiltrating lymphocytes (TIL), due to several encouraging
studies reporting on more ,50% response as a second-line
approach [33–35]. Nonetheless, several drawbacks to TIL-based
therapy, such as the need for surgery to obtain tumor tissue, the
long time and high costs required to develop sufficient numbers of
TIL, mandates the development of alternative or complementary
cell-based approaches.
Here we present a new concept for augmenting anticancer activity
of NK cells, which is based on NKLR/NKLR-ligand matching and
is completely independent of KIR/KIR-ligand mismatching. The
feasibility of NKLR-based selection of donors and the direct
correlation with anti tumor function are shown in malignant
melanoma as a lead example. This approach may be implemented
in solid malignancies and potentially in hematological malignancies,
either independently or in adjunction to other modalities.
Materials and Methods
Ethics Statement
This study was approved by an Institutional Review Board. All
subjects gave their written informed consent according to the
Declaration of Helisnki.
Cells
Primary melanoma cells were derived from surgically removed
specimens obtained from melanoma patients as part of an ongoing
clinical trial NCT00287131. Cells were grown and maintained as
formerly reported [36–37]. C1R cells stably transfected either with
an empty vector (C1R/Mock) or with the NKG2D-ligand ULBP1
(C1R/ULBP1) were kindly provided by Dr Ofer Mandelboim
(Lautenberg Center of Immunology, Hadassah Medical School of
Hebrew University, Jerusalem, Israel).
Antibodies
The following fluorophore-conjugated monoclonal antibodies
were used in this study (all from R&D Systems, Minneapolis, MN,
USA): anti-CD3-FITC, anti-CD56-PE/Cy5.5, anti-CD16-PE,
anti-NKG2D-APC (clone 149810), anti-NKp46-APC (clone
195314), anti-KIR3DL1-APC, anti-KIR2DL1-PE and anti-
KIR2DL2-PE. The monoclonal antibodies anti-NKp30-PE and
anti-NKp44-PE were purchased from Miltenyi Biotech (Bergisch
Gladbach, Germany). PE-conjugated goat anti human F(ab)2
fragments (Jackson Immunoresearch, West Grove, PA USA) were
used as secondary reagent for detection of Ig-fusion proteins.
NKLR-Ig fusion proteins
The cDNA of extracellular portion of various NKLRs was fused
in frame to the cDNA of the Fc portion of human Ig. The NKLR-
Ig fusion proteins were produced in COS-7 cells and purified on a
protein G column as previously described [11]. Proteins were
routinely tested in SDS PAGE for degradation. NKLR-Ig fusion
proteins were kindly provided by Dr Ofer Mandelboim.
Flow cytometry
Two hundred thousand cells per well were seeded in 96-U
shaped microplates and incubated in 50 ml of PBS/25% human
serum (Sigma, Rehovot, Israel) for 10 minutes on ice for blocking.
The appropriate antibody mixture diluted in 50 ml of FACS
medium (PBS, BSA 0.5%, sodium azide 0.02%) was further added
onto the cells and incubated for 30 minutes on ice under dark
conditions. Plates were centrifuged at 400 g for 6 minutes in 4uC,
supernatant removed, and each well washed with 200 ml of FACS
medium.
Melanoma patients and healthy donors
Peripheral blood was obtained from 40 melanoma patients with
clinical evidence of disease at stage IV according to AJCC staging
system, or from 30 healthy donors. Peripheral blood lymphocytes
were isolated using density gradient centrifugation and deep frozen
until use.
Enrichment of NK cells
Peripheral blood mononuclear cells (PBMCs) of healthy donors
were isolated from Leukapheresis or Buffy Coat by ficol density-
gradient centrifugation. Only clinically approved reagents were
employed, to enable potential compatibility in the future. NK cells
were enriched from PBMCs using a CD3
+ depletion kit
(Miltenyibiotec, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions. In short, CD3
+ T cells were
NKLR/NKLR-Ligand Matching
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beads. Depletion of the magnetically labeled cells was performed
through two succeeding columns, LS and LD. Isolated cells were
washed with PBS. The CD3
+ T cell contamination was
consistently lower than 1% (while using LD column alone resulted
in 2–3% of CD3
+ T cell remnant).
Expansion and activation of NK cells
To initiate expansion, CD3-depleted cells were re-suspended in
one of the analyzed growth mediums: CellGro (Mediatech Inc) or
X-VIVO 10 medium (Lonza, Verviers Sprl, Belgium) containing
5% HS (Gemini Bio-Products, West Sacramento, USA; Blood
bank, Magen David Adom, Tel-Hashomer, Israel), 1% penicillin-
streptomycin (Lonza). Cultures were supplemented with irradiated
(5000rad) allogeneic PBMCs derived from two healthy donors as
feeder cells and 500 IU/ml IL-2 (Proleukin, Chiron B.V.,
Amsterdam, Netherlands). Cells were cultured in 5% carbon
dioxide-air humidified atmosphere at 37uC. On day 5 of the
expansion, half of the medium was replaced by fresh medium. A
secondroundof‘‘feedercells’’wassupplementedonday7.Every2–
3 days total viable cell number was determined and medium was
added to attain a final concentration of approximately 0.5–
0.8610
6cells/ml. Cells were expanded for a total of three weeks,
while at different time points throughout the culture total cell counts
and NK purity were determined and portions of the culture frozen.
Cytotoxicity assays
Cytotoxicity assays based on PI co-staining of CFSE-labeled
target cells were performed precisely as described [37]. Briefly,
cytotoxicity assays were performed by PI costaining of carboxy-
fluorescein diacetate succinimidyl ester (CFSE)-labelled target
cells; 5610
6 target cells were labeled with 2.5 mM CFSE, which
strongly labels cells and allows differentiation between target and
effector cells. Ten thousand labelled target cells were coincubated
in 96 U-shaped microplates with given amounts of effector cells for
5 hr in a humidified 5% CO2 incubator. Killing rate was assessed
by the percentage of PI costaining cells out of gated CFSE-labelled
cells. In all experiments the percentage of PI-positive CFSE-
labelled cells in wells cultured without effectors did not exceed
15%. Blocking of NKG2D or NKp30 was performed by pre-
incubation of NK cells with 2 mg/ml of anti NKG2D (R&D
Systems, Minneapolis, MN, USA) or with 4 mg/ml of anti NKp30
(BioLegend, San Diego, CA, USA, Clone P30-15), respectively, for
30 minutes prior to incubation with target cells.
Statistical analysis
Aparametric t-test (Mann-Whitney test), aparametric ANOVA
(Kruskal-Wallis test) and Spearman’s correlation test were
performed with GraphPad PRISMH statistical software.
Results
NKG2D-mediated killing correlates with NKG2D
expression level by NK cells
The contribution of an individual NKLR canbe directly tested in
a cell system based on parental cells devoid of the appropriate lysis
ligand, and stable transfectants in which the ligand is expressed
ectopically. C1R cells were stably transfected either with one of the
knowncellularligandsforNKG2D,ULBP1(C1R/ULBP1),orwith
an empty vector (C1R/Mock). Both cells were concomitantly tested
in killing assays with various primary bulk NK cells. The difference
between killing of C1R/ULBP1 and of C1R/Mock reflects the
specific killing activity mediated by NKG2D. For example, 20%
killing of C1R/Mock, as compared to 37% killing of C1R/ULBP1
(P value,0.01), were observed with primary bulk NK culture NK-
A.K. (Figure 1A). The NKG2D expression profile on NK-A.K. is
presented on Figure 1B. This implies that the specific killing activity
mediated directly through NKG2D was 17%. Expression intensity
of NKG2D on NK cells is expressed as fold above background
(FAB), which is determined by the ratio between specific staining
and background staining intensity. Next, eight different primary
bulk NK cultures derived from healthy donors that varied in the
expression intensity of NKG2D, were tested in killing assays using
the C1R cell system. A remarkable, statistically significant, direct
correlation (Spearman’s r=1, p value,0.0001) was observed
between NKG2D expression and the magnitude of killing mediated
through NKG2D, determined as indicated above (Figure 1C).
These results clearly show that killing efficiency is directly affected
by the expression intensity of an NKLR, provided that the
appropriate ligand is present. Although it is impossible to perform
such assays with other NKLRs as the cellular ligands are still mostly
undefined, it is conceivable that a similar rule applies as well.
Figure 1. NKG2D-mediated killing directly correlates with the strength of NKG2D expression. Killing rates of C1R cells transfected with
an empty vector (C1R/Mock, gray bars) or with the NKG2D-ligand ULBP1 (C1R/ULBP1, black bars) by a representative bulk NK culture NK-A.K. Effector-
to-target ratio was 5:1. ** indicates P value,0.01. (B) NKG2D staining phenotype on a representative bulk NK culture NK-A.K. (C) Correlation between
NKG2D expression (X-axis) and percent specific killing via NKG2D (Y-axis). FAB stands for fold above background, which is the ratio between specific
and background staining intensity. The percent specific killing via NKG2D is the difference between killing of C1R/ULBP1 to C1R/Mock by the effector
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healthy donors
In order to test whether a considerable variability exists in
NKLR expression, we have analyzed the expression profile of
CD16, NKp30, NKp46 and NKG2D in 20 healthy donors.
Analysis was performed on gated NK cells, defined as CD3
2/
CD56
+ cells (Figure 2, left panels). Various expression patterns
were noted, for example; Donor 1, in which ,90% of the NK cells
were positive for CD16, NKG2D, NKp30 and NKp46, yet small
subpopulations that lacked one or more of the receptors were
clearly observed (Figure 2, upper panels); Donor 2, in which a low
expression of NKG2D and CD16 (,50%) was observed, despite a
high expression of NKp30 and NKp46 (.90%) (Figure 2, middle
panels); Donor 3, in which ,50% of the NK cells were NKG2D
positive and most were CD16 negative. Approximately 35% co-
expressed NKp30 and NKp46, while ,60% did not express either
one. Small subpopulations, which expressed only one of the
receptors, were detected (Figure 2, lower panels). Staining for
NKp44 was negative (data not shown), as this receptor is up-
regulated only following activation [11].
The receptor expression profile of 20 healthy donors, including
both the percentage of expression of each individual receptor, and
its magnitude of expression, were analyzed (Figure 3). Consider-
able donor variability was clearly evident in both parameters
among all NKLRs tested (Figure 3). These results provide at least a
partial explanation for the different reactivity usually displayed by
NK cells derived from different donors.
Kinetics of NKLR expression profile on NK cells
Periodic fluctuations in NKLR expression in a certain range
could account for the differences between healthy donors observed
above. We have therefore analyzed NKLR expression profiles in
seven different healthy donors longitudinally. Four serial blood
samples were obtained from each healthy donor over a period of 2
months (roughly every 2–3 weeks). Peripheral blood lymphocytes
were purified on a density gradient from all samples and frozen.
Figure 2. NKLR profile analysis on gated NK cells. Figure shows the NKLR analysis of 3 different donors, as indicated in the left. NK cells were
defined as CD56
+CD3
2 cells, as depicted in the left vertical panel. Gated NK cells were further co-stained for NKG2D and CD16 (central vertical panel)
or for NKp46 and NKp30 (right vertical panel). Circles highlight various subpopulations.
doi:10.1371/journal.pone.0005597.g002
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were thawed and analyzed in the same experiment. The
expression profiles of all NKLRs tested were relatively stable over
2-month period (Figure 4). Only minor variations could be
occasionally observed. Nevertheless, the major characteristic
differences between some of the donors were clearly maintained
Figure 3. Inter-donor variability in NKLR expression phenotype. Each NKLR was tested on gated NK cells and is presented in a different
panel, as indicated. Each dot represents a different healthy donor (N=20).
doi:10.1371/journal.pone.0005597.g003
Figure 4. NKLR expression phenotype is stable over time. Each NKLR was tested on gated NK cells and is presented in a different panel, as
indicated. Each shape represents a different healthy donor (N=7).
doi:10.1371/journal.pone.0005597.g004
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AZ was stable and remained very distinct from either donor AK
(displayed high FAB) or donor YC (displayed high percentage)
(Figure 4). These results indicate that although NKLR expression
profile on NK cells may vary considerably among different donors,
it is generally stable over time in each healthy donor.
Melanoma cells are recognized by certain NKLRs
The melanoma staining profiles by five different NKLRs,
including NKp44, NKp46, NKp30, NKG2D and CD16, were
tested. The cellular ligands of these receptors are still unknown,
except for NKG2D. Therefore, recombinant chimeric receptors
fused to the constant portion of human Ig were generated as
described in ‘‘Materials and Methods’’. Eight different primary
melanoma cell cultures were tested, all derived from metastatic
lesions. A clear recognition pattern by NKp44-Ig, NKp30-Ig and
NKG2D-Ig was observed (Figure 5), as opposed to little or no
binding of NKp46-Ig and CD16-Ig (Figure 5). Specifically,
NKp44-Ig bound all eight melanoma lines, and NKG2D-Ig as
well as NKp30-Ig bound the same seven out of eight melanoma
lines. The binding of NKp30-Ig was generally lower than NKp44-
Ig and NKG2D-Ig (Figure 4), but this does not necessarily attest
for a lesser role of NKp30. No binding of NKp46-Ig or CD16-Ig
could be observed to any of the melanoma lines tested (Figure 5).
These results suggest that NK-mediated control of melanoma cells
is mediated mainly through certain receptors.
Abnormal NKLR expression by peripheral blood NK cells
among melanoma patients
The expression profiles of NKp30, NKp46, CD16 and NKG2D
were tested on peripheral blood, unmanipulated, NK cells. Blood
specimens were collected from 30 healthy donors and 40 stage IV
melanoma patients with clinical evidence of disease. A significantly
lower percentage of NK cells expressed NKp30, CD16 and
NKp46 in stage IV melanoma patients, as compared to healthy
donors (Figure 6). The potential clinical significance of the NKp30
down-regulation is highlighted by its importance in recognizing
melanoma cells, as suggested by the results described in Figure 5.
On the other hand, CD16 was substantially down-regulated in
melanoma patients (Figure 6) and did not directly bind to
melanoma cells (Figure 5). CD16 functions alternatively as a main
Fc receptor mediating antibody dependent cell cytotoxicity. In
addition, despite the importance of NKG2D in recognizing
melanoma cells (Figure 5), no substantial differences were observed
between stage IV melanoma patients and healthy donors
(Figure 6). Little or no expression of NKp44 was observed,
probably as it is induced only following activation (data not
shown). Collectively, these observations imply that down-regulated
NKLR expression, particularly of NKp30, by NK cells in
melanoma patients may affect their ability to recognize and
eliminate tumor cells.
Consistent changes in NKLR expression during NK ex vivo
expansion
Most forms of adoptive cell immunotherapy require a large
number of transferred cells [38]. The long term proliferative
potential of NK cells ex vivo and the variations in NKLR expression
were thus studied. Adhering to clinically approved protocols,
CD3-positive cells were depleted from peripheral blood lympho-
cytes derived from seven healthy donors. This resulted in
enrichment of NK cells to around 30% (Figure 7A), as confirmed
by CD3/CD56 double staining (data not shown). Some of the
CD3-depleted cells (Day 0) were designated for overnight
activation with 500 IU/ml IL-2 (Day 1), while others were rapidly
expanded as detailed in ‘‘Materials and Methods’’. Overnight
activation with IL-2 had little effect on both purity and fold
expansion (Figure 7A). Rapid expansion was stopped after 14 or
21 days. The average fold of cell expansion was 44 and 300,
respectively. The average NK purity rates were 76% and 80%,
respectively (Figure 7A). Most of the remaining cells were T cells,
mainly CD8
+ cells (data not shown). More than 97% of the cells
were viable and were not stained by Propidium Iodine at any time
point (data not shown). Thus, NK cells can be effectively and
expanded in clinically compatible conditions, with an obvious
numerical benefit over simple overnight activation with IL-2.
The expression intensities of NKG2D, NKp30, NKp46, CD16
and NKp44 were monitored on NK cells during activation and
expansion. Due to the variability in NKLR profiles among
different healthy donors (Figure 3), NKLR expression had to be
normalized. Normalization was performed by dividing the fold
above background (FAB) of certain NKLR on expanded culture
by the FAB of the same NKLR on the corresponding unactivated
NK cells gated from un-manipulated peripheral blood lympho-
cytes. FAB calculations are based on the median fluorescence
intensity (MFI) parameter. The CD3-depletion process did not
affect the NKLR expression profiles of unactivated NK cells
(Figure 7B). A moderate, yet statistically significant enhancement
in the expression of NKG2D, NKp30 and NKp44 was observed
following overnight activation with IL-2 (P value,0.05). There
were no changes in the expression of NKp46 and CD16
(Figure 7B). During rapid expansion process, the various receptors
were differentially regulated. NKG2D was strongly induced by
Figure 5. Pattern of NKLR-ligands on primary melanoma cells. Figure shows the median fluorescence intensity (MFI) of the binding of various
NKLR-Ig fusion proteins to primary melanoma cells, as indicated in the figure. Figure shows a representative experiment.
doi:10.1371/journal.pone.0005597.g005
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5597Figure 6. NK NKLR expression profile in healthy donors vs. melanoma patients. The expression profile of each NKLR is presented in an
independent panel, as indicated. Each dot represents either a healthy donor or a melanoma patient. Blood specimens were collected from 30 healthy
donors and 40 stage IV melanoma patients with clinical evidence of disease. Y-axis denotes the percent of NKLR-positive cells out of gated NK cell.
Horizontal lines represent median values. P value under each panel was calculated with an aparametric t-test and represents the statistical
significance of the difference between median values.
doi:10.1371/journal.pone.0005597.g006
Figure 7. Expression of NKLRs on NK cells during activation and expansion. (A) Ex vivo expansion of peripheral blood NK cells. Figure
shows the average results of NK cultures derived from different donors (N=7). % NK purity was determined by double staining for CD3 and CD56 in
flow cytometry. CD3-depleted cells (Day 0) were either activated overnight with 500 IU/ml IL-2 (Day 1) or underwent rapid expansion for 14 (Day 14)
or 21 days (Day 21). Fold expansion was calculated relatively to the amount of NK cells in Day 0. (B) NKLR expression during ex vivo expansion. All NK
cultures were independently stained for the indicated NKLRs. Expression of NKLRs in each donor was normalized according to the corresponding
expression on gated NK cells by the un-manipulated peripheral blood mononuclear cells (PBMC). Figure shows the average of normalized results on
all healthy donors tested (N=7). Error bars represent standard error. * denotes a statistical significance of P value,0.05. ** denotes a statistical
significance of P value,0.01.
doi:10.1371/journal.pone.0005597.g007
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although it remained higher than unactivated NK cells (P
value,0.05). The enhanced expression of NKp30 and NKp44
was further mildly but significantly increased during rapid
expansion (Figure 7B, P value,0.05). The expression of CD16
was significantly decreased during rapid expansion by day 14 (P
value,0.05), and even more by day 21 (P value,0.01) (Figure 7B).
The expression of NKp46 remained unchanged throughout the
expansion process (Figure 7B). These results clearly show that
overnight activation of NK cells with IL-2 manifests in enhanced
expression of various NKLRs. However, strong and prolonged
activation during rapid expansion further significantly affects
NKLR expression profile, in a predictable and consistent manner.
The rapid expansion process mainly affected the NKLRs
identified as crucial in recognition of melanoma cells (Figure 5).
These combined observations indicate that rapid expansion may
be superior to overnight activation with IL-2 by inducing the
expression of relevant NKLRs.
Association between NKLR expression prior to activation
and post ex vivo expansion
NKLR expression profile varied among healthy donors
(Figure 3) and could be predictably manipulated during rapid
expansion process (Figure 7). We next tested whether there is an
association between initial NKLR expression profile on unac-
tivated NK cells and NKLR expression following ex vivo
expression. A striking direct association (Spearman’s r=0.97, P
value,0.01) was observed between initial expression of NKG2D
and its expression at day 14 of ex vivo expansion (Figure 8). Higher
expression levels of NKG2D were expressed following 14 days of
ex vivo expansion on NK cells that initially expressed higher levels
of NKG2D prior to activation. NKG2D expression was markedly
and consistently lower at day 21, and had no correlation with
initial NKG2D expression (Figure 8). Initial expression of NKp30
was directly associated with NKp30 expression at both days 14
and 21 (r=0.82, P value=0.05 and r=1, P value,0.01) (Figure 8).
In contrast, there was no association between the initial expression
level of NKp46 or CD16 with their expression following rapid
expansion process (Figure 8). These results show that for some
NKLRs, the induction following ex vivo stimulation is predictable
and depends on the basal expression intensity (donor-specific
characteristics) and on length of expansion process (culture-specific
characteristics).
NKLR expression profile correlates with killing efficiency
of allogeneic melanoma cells
NK cells were derived and cultured from healthy donors. Cells
were analyzed for NKLR expression profiles and killing activity
Figure 8. Correlation between NKLR expression prior to and after rapid expansion. Each NKLR was tested on gated NK cells and is
presented in a different panel, as indicated. NK cultures from different donors (N=7) were tested at day 14 (black squares) and at day 21 (X’s) of rapid
expansion protocol (REP). The NKLR expression prior to rapid expansion was tested on un-manipulated peripheral blood NK cells. Each dot represents
the average of at least three staining experiments. FAB - fold above background.
doi:10.1371/journal.pone.0005597.g008
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were positively stained by the NKp44-Ig, NKp30-Ig and NKG2D-
Ig fusion proteins (Figure 5). The relative contribution of NKLRs
to the killing of Mel008 between different NK donors could be
compared in HLA-KIR matched or mismatched setups. However,
the expression of KIR varies significantly among different donors
[39]. This would make the interpretation of NKLR contribution
impossible in the matched HLA-KIR setup, as the overall killing
would be skewed by the varying inhibitory signals. In addition, the
expression of various KIRs alters during ex vivo expansion
(Figure 9A). We show that the expression of KIR3DL1, KIR2DL1
and KIR2DL2 is enhanced during expansion, while KIR3DL1
and KIR2DL2 tend to return to basal levels after 21 days in
culture (Figure 9A). This observation renders the analysis of
NKLR contribution in the same NK culture at different time
points during expansion problematic as well.
On the other hand, in the HLA-KIR mismatched setup, the
inhibitory effect by KIRs is reduced to minimum [25–28]. The
HLA of Mel008 cells was fully genotyped, and the cells were found
to be homozygous for HLA-C from the C1 KIR-Ligand subgroup.
Further, they did not express other HLA –A or –B alleles that are
recognized by known KIRs (Table 1). Two healthy donors that
Figure 9. Enhanced expression of NKLRs correlates with improved cytotoxicity against melanoma cells. (A) KIR expression during ex
vivo expansion. All NK cultures were independently stained for the indicated KIRs. Expression of KIRs in each donor was normalized according to the
corresponding expression on gated NK cells by the un-manipulated peripheral blood mononuclear cells (PBMC). Figure shows the average of
normalized results on all healthy donors tested (N=7). Error bars represent standard error. * denotes a statistical significance of P value,0.05. (B) The
expression of each NKLR was tested on two representative bulk NK cultures on day 1 and day 14 of ex vivo expansion process, as indicated in the
figure. Expression is presented as median fluorescence intensity (MFI). (C) NK#1 and (D) NK#2 cultures were tested in killing assays against Mel008
cells in various effector-to-target (E:T) ratios. NKG2D or/and NKp30 on NK cultures #1 and #2 at day 14 were blocked by pre-incubation with mAb at
a concentration of 2 mg/ml or 4 mg/ml, respectively. Figure shows a representative experiment. (E) NK cells with low expression of NKp30 were
derived from melanoma patients (NKmel#1 and NKmel#2) and tested in killing assays against Mel008 cells in an E:T of 20:1. NKG2D or/and NKp30
were blocked as described above. Figure shows a representative experiment.
doi:10.1371/journal.pone.0005597.g009
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were identified, and were thus completely mismatched with the
Mel008 cells (Table 1). Since the melanoma cells did not express
KIR-ligands from the HLA-A or –B alleles, the fact that the NK
donors were positive for these alleles was irrelevant. NK cells were
derived from these donors, expanded ex vivo and stained for the
expression of NKG2D, NKp30, NKp44 and NKp46. The
expression of NKG2D and NKp30 on NK cells was higher in
Donor #1 than in Donor #2 before, mainly after ex vivo expansion
(Figure 9B). Following ex vivo expansion, the expression of NKp44
was similarly induced in both donors, and the expression of
NKp46 was not significantly affected (Figure 9B). Concurring with
the differences in expression of NKG2D and NKp30, NK#1 cells
displayed higher cytotoxic activity than NK#2 cells in all effector-
to-target ratios tested (Figure 9C–D). At day 1 there was only a
small difference in the killing activity of NK#1 and NK#2, which
fitted the small absolute difference in NKG2D and NKp30
expression (Figure 9B). NK cells from both donors at day 14 of ex
vivo expansion displayed higher cytotoxic activities than in day 1
(Figure 9C–D). The differences between NK cultures at day 1 and
at day 14 may also be accounted to the enhanced NKp44
(Figure 9B). The involvement of NKG2D and of NKp30 in the
recognition and elimination of Mel008 cells was evident by the
substantial reduction in cytotoxic activity in the presence of a
blocking anti-NKG2D mAb or a blocking anti-NKp30 mAb.
Blocking of both NKG2D and of NKp30 further decreased the
elimination of Mel008 additively, but not abolish it completely
(Figure 9C–D). Residual killing activity of Mel008 cells is probably
mediated via other NKLRs such as NKp44. Similar results were
observed with additional NK cultures tested (data not shown). In
conclusion, higher killing efficiency of NK cell derived from
certain donors, as well as at various time points of expansion
process, correlates with the expression intensity of the relevant
NKLRs.
Finally, NK cells with low NKp30 expression were derived from
2 melanoma donors (Figure 6) and tested against HLA-KIR
mismatched Mel008 cells (NKmel#1 and NKmel#2, Table 1).
An intermediate level of basal killing activity was observed. A
minor effect was observed in the presence of the anti NKp30
blocking antibody, as compared to a clear blocking effect observed
with the anti NKG2D mAb (Figure 9E). The combination of the
two blocking antibodies did not yield an additive effect (Figure 9E),
as compared to the effect on healthy donor NK cells (Figure 9C–
D). These results indicate that the decreased expression of NKp30
on the surface of NK cells in melanoma patients may culminate in
partially impaired response against the melanoma cells.
Discussion
Cellular immunotherapy holds a great promise in both
hematological and solid malignancies. Clinical attempts to employ
the anti-neoplastic potential of autologous NK cells were
conducted in the past, without achieving substantial beneficial
results [23–24]. Although failure may emanate from autologous
KIR/KIR-ligand interactions, our present study also suggests that
at least in melanoma, autologous NK cells have decreased
expression of stimulating NKLRs (Figure 6). Several years ago
the theory of KIR/KIR-ligand mismatching was developed for
allogeneic setting in order to decrease the inhibitory interactions
and thus facilitate anti-neoplastic effect. This hypothesis was
successfully implemented in AML [26–27], but failed in acute
lymphocytic leukemia (ALL) patients [26]. The lack of compelling
results of this approach in ALL could be explained by paucity of
NKLR-ligands on ALL cells [26].
In this study we show that NKLR/NKLR-ligand matching
directly affects and improves NK killing activity. A direct
correlation between the magnitude of NKG2D-mediated killing
and the magnitude of NKG2D expression by NK cells was
observed (Figure 1). It is expected that a similar rule applies for
other NKLRs. Efficient matching of NKLRs to cancer cells relies
on the hypothesis that each cancer histotype is recognized mainly
by certain NKLRs. We show here, for example, that melanoma
cells derived from different patients are predominantly recognized
by three NKLRs: NKG2D, NKp30 and NKp44 (Figure 5). These
receptors are therefore presumed to have a dominant role in NK
cell response to melanoma, and should therefore be the focus of
NKLR/NKLR-ligand matching efforts in this case. Other cancer
histotypes may be recognized by other NKLRs. Indeed, killing
assays in a HLA-KIR mismatched setup, which neutralizes
confounding inhibitory effects, show that NK cells with higher
expression of the dominant NKLRs display enhanced cytotoxic
activity (Figure 9). It is currently accepted that killing activity
reflects the overall activating and inhibiting signals [1], and thus
NKLR/NKLR-Ligand matching will enhance NK stimulating
signals in the presence of other inhibitory signals.
The specific involvement and additive effect of NKG2D and
NKp30 were evident by the partial abolishment of cytotoxic
activity in the presence of blocking monoclonal antibodies
(Figure 9). Residual killing activity is probably enabled via
NKp44. Further, we found that NKp30 is expressed in
significantly lower levels among NK cells of metastatic melanoma
patients as compared to healthy donors (Figure 6), and
consequently that blocking of NKp30 did not alter the anti
Table 1. HLA haplotype of melanoma and NK donors.
HLA-A HLA-B HLA-C
Allele1 Allele2 KIR-Ligand Allele1 Allele2 KIR-Ligand Allele1 Allele2 KIR-Ligand
C1 C2
Mel008 A*02 A*02 NO B*15 B*15 NO Cw*3 Cw*3 YES NO
NK#1 A*01 A*03 YES B*37 B*57 YES Cw*6 Cw*6 NO YES
NK#2 A*30 A*31 NO B*13 B*35 YES Cw*4 Cw*6 NO YES
NKmel#1 A*01 A*01 NO B*35 B*35 NO Cw*4 Cw*4 NO YES
NKmel#2 A*01 A*24 NO B*35 B*35 YES Cw*6 Cw*6 NO YES
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whether this observation is a melanoma-driven effect (active
suppression of NKp30 expression), or whether individuals with a
natural lower expression of NKp30 are more susceptible to the
development of melanoma (a selection effect).
Allogeneic NK cells could be employed for the treatment of
metastatic solid malignancies in an adoptive transfer approach.
Allogeneic NK ACT approach have several important advantages:
1) NK cells can be easily obtained from the peripheral blood; 2)
NK cells do not require specific antigenic stimulation or selection;
3) They require significantly lower in vivo concentrations of IL-2 for
maintenance [30], which might have a direct impact on treatment
tolerability and toxicity [40]; 4) Allogeneic NK cells probably
cannot eliminate normal recipient cells, because they do not
express significant levels of the NKLR-ligands [41], and hence are
not involved in mediating GVH effects, but rather protect from
them [26]; 5) NK cells can be modularly combined with other
therapeutic modalities such as antibodies or other autologous
cellular products; 6) Allogeneic sources increases the pool of
potential donors. Following the success in AML, the potential of
KIR/KIR-ligand mismatching was preliminarily studied in solid
malignancies. Preclinical studies have demonstrated the enhanced
in vitro efficacy of KIR/KIR-ligand mismatching against melano-
ma and renal cell carcinoma (RCC) cells [28]. Clinical studies
were performed with peripheral blood NK cells from haploiden-
tical donors that were activated ex vivo with IL-2 overnight in
AML, melanoma and RCC patients [30]. These studies
demonstrated the safety of this modality, as no severe adverse or
toxic effects were recorded [30]. Our present results show a
significant enhancement in both NKLR expression profile and
anti-neoplastic activity of NK cells activated overnight with IL-2
compared with NK cells that underwent ex vivo expansion, with the
latter being clearly superior (Figures 7, 9). Therefore, these data
provide a motivation for ex vivo expansion to significantly improve
the clinical results with allogeneic NK ACT.
This report, however, further suggests that certain healthy
donors with maximal expression of certain NKLRs could
theoretically yield NK cells with improved activity against certain
cancer cells. It was reported that all mature peripheral blood NK
cells express NKG2D and NKp46, and the majority of NK cells
express other NKLRs such as NKp30 and CD16 as well [1–5]. In
contrast, our analysis shows that there is a considerable variability
among healthy donors in percentage of receptor-positive NK cells
and in magnitude of expression (Figures 2, 3). In some cases, the
majority of the NK cells indeed co-express all NKLRs tested, while
in other cases, we detected various NK subpopulations that were
negative for one or more of the NKLRs (Figure 2). Weak or no
expression of NKLRs by peripheral blood NK cells was shown in
patients early after bone marrow transplantation, as indicator for
immature phenotype [42]. It is not reasonable that the majority of
NK cells in the peripheral blood of healthy donors are immature,
but as demonstrated with KIR-negative NK cells [8–10], their
proportion could be significant. Furthermore, it should be noted
that in many of the previous studies, primary NK cells were
characterized following in vitro purification, activation and culture
for at least several days. We show that at least the expression of
NKp30 and NKG2D is directly induced by in vitro activation and
culturing (Figure 7B). Other differences may also be attributed to
the affinity of different monoclonal antibodies used.
This donor variability would potentially allow selection of
optimal donors according to NKLR expression. In the case of
melanoma, for example, healthy donors with maximal expression
of NKp30, NKp44 and NKG2D would be favored. Since NKp44
is only rarely found in normal peripheral blood, as it is activation-
induced [14], maximal expression of NKG2D and NKp30
remains the main criteria for selection of donors. It is possible
that other malignant cells would be recognized mainly by a
different panel of NKLRs, which would implicate in different
selection criteria of optimal NK donors. Thus, although the
present study focuses on melanoma, this approach might still fit
other malignancies as well, including both hematological and solid
origins. Moreover, this approach is not limited by heterozygous
expression of KIR-ligands, which is considered as a contraindi-
cation in KIR/KIR-ligand mismatching [26]. We show that
NKLR expression profile is generally stable and reproducible
among healthy donors, at least over two months (Figure 4). Our
studies should be expanded and performed on additional healthy
donors and over an extended period of time, to fortify these
observations. Another important point for future studies is
standardization of NKLR expression, for example by normaliza-
tion according to standard cells, or by employment of a different
method such as quantitative real time PCR.
We show that ex vivo expansion process has profound, yet
generally consistent and predictable, effects on NKLR expression
profiles. Indeed, NK cells following 14 or 21 days of ex vivo
expansion displayed significantly enhanced NKp30, NKp44 and
NKG2D expression profiles as compared to overnight activation
with IL-2 or fresh cells (Figure 7). In addition, dynamics of NKLR
expression patterns over time during ex vivo expansion were noted,
as evident by the statistically significant differences between
NKLR profiles on day 14 and day 21 (Figure 7). Thus, various
cultivation conditions might be employed to differentially
maximize expression of certain NKLRs of interest. Moreover,
initial differences between donors were maintained even following
ex vivo expansion, e.g. NKG2D
high donors yielded NK cells with
highest expression of NKG2D (Figure 8), which translates into
higher cytotoxic activity (Figure 9). Further investigations would be
required for development of NKLR-guided specific cultivation
conditions. It should be noted that ex vivo expansion significantly
enhanced the expression of various inhibitory KIRs as well
(Figure 9). This induction may diminish the enhanced NKLR-
mediated effect, but an HLA-KIR mismatched setup can alleviate
the inhibition, as shown by others [26,30]. In addition, the NK
cultivation protocols employed in this study resulted in more than
20% contamination of T cells, which obviously precludes its
clinical use in the present form, due to potential graft versus host
disease. Future protocols can be modified, for example: to add an
additional T cell depletion round, add an additional NK positive
selection round or alter culture conditions.
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